2024
Identifying G6PC3 as a Potential Key Molecule in Hypoxic Glucose Metabolism of Glioblastoma Derived from the Depiction of 18F‐Fluoromisonidazole and 18F‐Fluorodeoxyglucose Positron Emission Tomography
Okamoto M, Yamaguchi S, Sawaya R, Echizenya S, Ishi Y, Kaneko S, Motegi H, Toyonaga T, Hirata K, Fujimura M. Identifying G6PC3 as a Potential Key Molecule in Hypoxic Glucose Metabolism of Glioblastoma Derived from the Depiction of 18F‐Fluoromisonidazole and 18F‐Fluorodeoxyglucose Positron Emission Tomography. BioMed Research International 2024, 2024: 2973407. PMID: 38449509, PMCID: PMC10917478, DOI: 10.1155/2024/2973407.Peer-Reviewed Original ResearchConceptsPositron emission tomographyF-FDGMRNA expressionOverall survivalGlucose metabolismF-FDG positron emission tomographyAssociated with poor overall survivalProtein expressionEmission tomographyGross total resectionPotential key moleculesFluorine-18 fluorodeoxyglucoseHypoxic conditionsDegree of glucose metabolismMolecular mechanisms of glucose metabolismAggressive primary brain tumorPoor overall survivalPrimary brain tumorKey moleculesTotal resectionPreoperative examinationIntratumoral hypoxiaPrognostic valuePoor prognosisBiomarkers of glioblastoma
2019
Influence of the scan time point when assessing hypoxia in 18F-fluoromisonidazole PET: 2 vs. 4 h
Kobayashi K, Manabe O, Hirata K, Yamaguchi S, Kobayashi H, Terasaka S, Toyonaga T, Furuya S, Magota K, Kuge Y, Kudo K, Shiga T, Tamaki N. Influence of the scan time point when assessing hypoxia in 18F-fluoromisonidazole PET: 2 vs. 4 h. European Journal Of Nuclear Medicine And Molecular Imaging 2019, 47: 1833-1842. PMID: 31781832, DOI: 10.1007/s00259-019-04626-8.Peer-Reviewed Original ResearchConceptsStandardized uptake valueWhite matter ratioWhite matterGray matterMean standardized uptake valueMethodsTwenty-three patientsScan time pointsPositron emission tomography (PET) tracerEmission tomography tracerMaximum tumorIntravenous injectionResultsAt 2Single injectionBrain tumorsUptake valueBrain tissueTumor hypoxiaTumorsTomography tracerTime pointsHypoxia imagingNormal ratioHypoxic tumorsPatientsSUVmax
2017
Players of ‘hypoxia orchestra’ – what is the role of FMISO?
Toyonaga T, Hirata K, Shiga T, Nagara T. Players of ‘hypoxia orchestra’ – what is the role of FMISO? European Journal Of Nuclear Medicine And Molecular Imaging 2017, 44: 1679-1681. PMID: 28634683, DOI: 10.1007/s00259-017-3754-9.Commentaries, Editorials and LettersQuantification of Tumor Hypoxic Fractions Using Positron Emission Tomography with [18F]Fluoromisonidazole ([18F]FMISO) Kinetic Analysis and Invasive Oxygen Measurements
Kelada OJ, Rockwell S, Zheng MQ, Huang Y, Liu Y, Booth CJ, Decker RH, Oelfke U, Carson RE, Carlson DJ. Quantification of Tumor Hypoxic Fractions Using Positron Emission Tomography with [18F]Fluoromisonidazole ([18F]FMISO) Kinetic Analysis and Invasive Oxygen Measurements. Molecular Imaging And Biology 2017, 19: 893-902. PMID: 28409339, PMCID: PMC5640490, DOI: 10.1007/s11307-017-1083-9.Peer-Reviewed Original ResearchConceptsPositron emission tomographyTumor hypoxic fractionHypoxic fractionEmission tomographyLung cancer radiotherapy patientsPO2 measurementsAbsolute tumor volumeC miceDirect pO2 measurementsBlood ratioClinical impactTumor volumeHypoxia quantificationSubcutaneous tumorsPurposeThe purposeTracer kinetic modelingRadiotherapy patientsPET imagingPatientsPO2 valuesScansPatlak modelTomographyTwo-compartmentTBR
2016
Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment
Yamaguchi S, Hirata K, Toyonaga T, Kobayashi K, Ishi Y, Motegi H, Kobayashi H, Shiga T, Tamaki N, Terasaka S, Houkin K. Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment. PLOS ONE 2016, 11: e0167917. PMID: 27936194, PMCID: PMC5148016, DOI: 10.1371/journal.pone.0167917.Peer-Reviewed Original ResearchConceptsFMISO accumulationOverall survivalFMISO PETBEV treatmentPartial responseRecurrent gliomaPre-treatment clinical factorsCox proportional hazards modelRecurrent glioma patientsSignificant prognostic factorsOverall survival differenceHumanized monoclonal antibodyProportional hazards modelLonger OSPET appearanceBevacizumab treatmentPrognostic factorsRANO criteriaSurvival benefitClinical factorsMRI findingsRetrospective studySurvival differencesChemotherapeutic optionsMRI appearanceHypoxic glucose metabolism in glioblastoma as a potential prognostic factor
Toyonaga T, Yamaguchi S, Hirata K, Kobayashi K, Manabe O, Watanabe S, Terasaka S, Kobayashi H, Hattori N, Shiga T, Kuge Y, Tanaka S, Ito YM, Tamaki N. Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor. European Journal Of Nuclear Medicine And Molecular Imaging 2016, 44: 611-619. PMID: 27752745, DOI: 10.1007/s00259-016-3541-z.Peer-Reviewed Original ResearchConceptsProgression-free survivalExtent of resectionStandardized uptake valuePositron emission tomographyGross tumor volumeFMISO positron emission tomographyMagnetic resonance imagingKarnofsky Performance ScaleOverall survivalTumor volumeGlioblastoma patientsHypoxia volumeFDG positron emission tomographyFluorodeoxyglucose positron emission tomographyPotential prognostic factorsTotal lesion glycolysisMetabolic tumor volumeHypoxic volumeVolume of interestGadolinium-enhanced T1-weighted MR imagesReference regionT1-weighted MR imagesCytoreduction surgeryFree survivalPrognostic factors18F-fluoromisonidazole (FMISO) PET may have the potential to detect cardiac sarcoidosis
Manabe O, Hirata K, Shozo O, Shiga T, Uchiyama Y, Kobayashi K, Watanabe S, Toyonaga T, Kikuchi H, Oyama-Manabe N, Tamaki N. 18F-fluoromisonidazole (FMISO) PET may have the potential to detect cardiac sarcoidosis. Journal Of Nuclear Cardiology 2016, 24: 329-331. PMID: 27071998, DOI: 10.1007/s12350-016-0495-2.Peer-Reviewed Original ResearchEvent-by-Event Continuous Respiratory Motion Correction for Dynamic PET Imaging
Yu Y, Chan C, Ma T, Liu Y, Gallezot JD, Naganawa M, Kelada OJ, Germino M, Sinusas AJ, Carson RE, Liu C. Event-by-Event Continuous Respiratory Motion Correction for Dynamic PET Imaging. Journal Of Nuclear Medicine 2016, 57: 1084-1090. PMID: 26912437, DOI: 10.2967/jnumed.115.167676.Peer-Reviewed Original Research18F-fluoromisonidazole positron emission tomography can predict pathological necrosis of brain tumors
Toyonaga T, Hirata K, Yamaguchi S, Hatanaka KC, Yuzawa S, Manabe O, Kobayashi K, Watanabe S, Shiga T, Terasaka S, Kobayashi H, Kuge Y, Tamaki N. 18F-fluoromisonidazole positron emission tomography can predict pathological necrosis of brain tumors. European Journal Of Nuclear Medicine And Molecular Imaging 2016, 43: 1469-1476. PMID: 26841941, DOI: 10.1007/s00259-016-3320-x.Peer-Reviewed Original ResearchConceptsPresence of necrosisBrain tumorsFMISO PETFMISO uptakeSevere hypoxiaFMISO PET/Brain tumor patientsPositron emission tomography (PET) tracerPositron emission tomographyEmission tomography tracerHistopathological necrosisPathological necrosisPoor prognosisSurgical strategyIntratumoral necrosisNeuroepithelial tumorsTumor resectionPathological diagnosisTumor patientsCerebellum ratioTreatment decisionsMethodsThis studyGroup 2Group 1Experienced neuropathologist
2015
Synthesis of [18F]FMISO in a flow-through microfluidic reactor: Development and clinical application
Zheng MQ, Collier L, Bois F, Kelada OJ, Hammond K, Ropchan J, Akula MR, Carlson DJ, Kabalka GW, Huang Y. Synthesis of [18F]FMISO in a flow-through microfluidic reactor: Development and clinical application. Nuclear Medicine And Biology 2015, 42: 578-584. PMID: 25779036, DOI: 10.1016/j.nucmedbio.2015.01.010.Peer-Reviewed Original Research
2014
[18F]-Fluoromisonidazole Positron Emission Tomography/Computed Tomography Visualization of Tumor Hypoxia in Patients With Chordoma of the Mobile and Sacrococcygeal Spine
Cheney M, Chen Y, Lim R, Winrich B, Grosu A, Trofimov A, Depauw N, Shih H, Schwab J, Hornicek F, DeLaney T. [18F]-Fluoromisonidazole Positron Emission Tomography/Computed Tomography Visualization of Tumor Hypoxia in Patients With Chordoma of the Mobile and Sacrococcygeal Spine. International Journal Of Radiation Oncology • Biology • Physics 2014, 90: 1030-1036. PMID: 25539367, PMCID: PMC4280072, DOI: 10.1016/j.ijrobp.2014.08.016.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCell HypoxiaChordomaFeasibility StudiesFemaleHumansMaleMiddle AgedMisonidazoleMultimodal ImagingNeoplasm Recurrence, LocalPhotonsPilot ProjectsPositron-Emission TomographyProspective StudiesProton TherapyRadiopharmaceuticalsRadiotherapy DosageRelative Biological EffectivenessSacrococcygeal RegionSpinal NeoplasmsTomography, X-Ray ComputedTumor BurdenConceptsHypoxic subvolumesGross tumor volumeFMISO PET/CTRadiation therapyLocal recurrenceTumor volumeSacrococcygeal spinePositron Emission Tomography/Computed TomographyRT dose escalationStage T2 tumorsEmission Tomography/Computed TomographyStandardized uptake valueMedian Follow-UpTreatment of chordomasChanges to treatmentVisualization of tumor hypoxiaDose escalationT2 tumorsTomography/Computed TomographyMetastatic diseaseRecurrent chordomaUptake valueClinical characteristicsTumor hypoxiaFollow-up
2013
Event‐by‐event respiratory motion correction for PET with 3D internal‐1D external motion correlation
Chan C, Jin X, Fung EK, Naganawa M, Mulnix T, Carson RE, Liu C. Event‐by‐event respiratory motion correction for PET with 3D internal‐1D external motion correlation. Medical Physics 2013, 40: 112507. PMID: 24320466, DOI: 10.1118/1.4826165.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Non-Small-Cell LungFluorine RadioisotopesHealthy VolunteersHumansHypoxiaImage Processing, Computer-AssistedImaging, Three-DimensionalInsulin-Secreting CellsKidneyLung NeoplasmsMisonidazoleMovementPancreasPositron-Emission TomographyRegression AnalysisReproducibility of ResultsRespirationSignal Processing, Computer-AssistedTetrabenazineX-Ray Microtomography
2010
Hypofractionation Results in Reduced Tumor Cell Kill Compared to Conventional Fractionation for Tumors With Regions of Hypoxia
Carlson DJ, Keall PJ, Loo BW, Chen ZJ, Brown JM. Hypofractionation Results in Reduced Tumor Cell Kill Compared to Conventional Fractionation for Tumors With Regions of Hypoxia. International Journal Of Radiation Oncology • Biology • Physics 2010, 79: 1188-1195. PMID: 21183291, PMCID: PMC3053128, DOI: 10.1016/j.ijrobp.2010.10.007.Peer-Reviewed Original ResearchConceptsTumor cell killingTumor hypoxiaCell killingRadiation fractionation schemesTumor biological effective doseBiological effective doseTumor cell killRegions of hypoxiaRadiotherapy regimenTreatment failureConventional fractionationNeck cancerStandard fractionationProstate cancerTumor cell populationFractionation schemeRadiation therapyTumor clonogensTumor oxygenationBlood vessels resultsCell killEffective doseAlternate fractionationResistant cellsHypoxia
1999
The potential for myocardial imaging with hypoxia markers
Sinusas A. The potential for myocardial imaging with hypoxia markers. Seminars In Nuclear Medicine 1999, 29: 330-338. PMID: 10534235, DOI: 10.1016/s0001-2998(99)80020-8.Peer-Reviewed Original Research
1984
Enhancement of artificial lung metastases by misonidazole
Rockwell S, Nierenburg M, Irvin C. Enhancement of artificial lung metastases by misonidazole. International Journal Of Radiation Oncology • Biology • Physics 1984, 10: 1395-1398. PMID: 6469763, DOI: 10.1016/0360-3016(84)90356-0.Peer-Reviewed Original ResearchConceptsArtificial lung metastasesLung metastasesHypoxic cell radiosensitizer misonidazoleEMT6 mouse mammary carcinoma cellsLung tumor formationMouse mammary carcinoma cellsEffect of treatmentMammary carcinoma cellsLung tumorsIntravenous injectionPhysiologic effectsLarge dosesRadiosensitizer misonidazoleSmall dosesSingle treatmentCarcinoma cellsMisonidazoleTumor formationMetastasisTreatmentDosesTumors
1982
Dose-response curves for predicting misonidazole-induced peripheral neuropathy.
Schwade J, Makuch R, Strong J, Glatstein E. Dose-response curves for predicting misonidazole-induced peripheral neuropathy. Journal Of The National Cancer Institute 1982, 66: 1743-50. PMID: 6288238.Peer-Reviewed Original ResearchConceptsPeripheral neuropathyLinear logistic regression analysisTotal cumulative doseLogistic regression analysisLogistic regression modelsDose-response curveCumulative AUCCumulative dosePlasma eliminationPlasma concentrationsNeuropathyLinear logistic regression modelPharmacokinetic parametersPharmacokinetic curveCancer treatmentToxic agentsRegression analysisAUCRegression modelsPatientsPharmacokineticsDoseMisonidazole
1980
Effect of excision repair on the mutagenesis of misonidazole.
Kacinski BM, Mroczkowski Z, Rupp WD. Effect of excision repair on the mutagenesis of misonidazole. American Journal Of Clinical Oncology 1980, 3: 69-71. PMID: 6993036.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply